Mylan Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN LABS
MYLAN LABS has sixty-seven approved drugs.
There are nine tentative approvals on MYLAN LABS drugs.
Drugs and US Patents for Mylan Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | DOXORUBICIN HYDROCHLORIDE | doxorubicin hydrochloride | INJECTABLE;INJECTION | 200170-001 | Oct 28, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Mylan Labs Ltd | IRON SUCROSE | iron sucrose | INJECTABLE;INTRAVENOUS | 212559-002 | Aug 8, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Labs Ltd | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 210072-001 | Jul 2, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Labs Ltd | SYMFI | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 022142-001 | Mar 22, 2018 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Labs Ltd | GLUCAGON | glucagon | INJECTABLE;INJECTION | 204468-001 | Dec 12, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Labs Ltd | COBICISTAT | cobicistat | TABLET;ORAL | 209986-001 | Feb 7, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

